RALEIGH, N.C., May 12, 2015 (GLOBE NEWSWIRE) -- PRA Health Sciences (PRA) is pleased to sponsor the first meeting of Quality Assurance (QA) experts in Russia. The Russian Regional Research Quality Association (RQA) Forum will facilitate knowledge sharing and the exchange of ideas and opinions in the QA community.
"We are very excited about this opportunity," said Stanislav Gneushev, Senior Director, QA, PRA Health Sciences and the Chair of the RQA Forum. "This forum is a chance to establish a strong QA community in Russia and to increase awareness about PRA Health Sciences' clinical research in Russia."
The RQA is an association which provides information to individuals concerned with the quality of research and development of pharmaceuticals, chemicals and medical devices. The Russian Regional RQA Forum Group was established in September 2014 with the following goals:
- Expand the influence and initiatives of the RQA and promote RQA goals among Russian QA professionals
- Create a community of QA experts in Russia to facilitate an exchange of ideas among the QA community
- Establish regular meetings of QA professionals
The first Russian Regional Forum will take place May 15, 2015. Representatives from global and local pharmaceutical companies and contract research organizations, as well as Russian regulatory authority and academy representatives have been invited to attend.
ABOUT PRA HEALTH SCIENCES
PRA Health Sciences is one of the world's leading global contract research organizations, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. At PRA, providing innovative solutions for our clients is what we do. Side-by-side with our clients, we strive to move drug discovery forward, helping them to develop life-saving and life-improving drugs. PRA has more than 11,000 employees working in 80+ countries providing comprehensive clinical development services across all phases. From full service clinical development to the pioneering Embedded Solutions™ model, PRA provides a broad spectrum of solutions that meet the demands of a diverse marketplace. PRA has worked on 100+ marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 50+ such drugs.
CONTACT: MEDIA INQUIRIES: Christine Rogers, Manager - Public Relations, Corporate Communications EMAIL: firstname.lastname@example.org PHONE: +1 919.786.8463 INVESTOR INQUIRIES: InvestorRelations@prahs.com
Source:PRA Health Sciences